High-density lipoprotein cholesterol increases following a short-term yoga-based lifestyle intervention: a non-pharmacological modulation

References

• Sans 5, Kesteloot H, Kromhout D.The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18:1231–48.
   Google Scholar
• The World Health Report: Shaping the future. World Health Organization: Geneva, 2003.
   Google Scholar
• Barter P. Gotta AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V. Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301–10.
   Google Scholar
• Yokokawa H, Yasumura 5, Tanno K, Ohsawa M, Onoda T, Itai K, Sakata K, Kawamura K, Tanaka F, Yoshida Y, Nakamura M, Terayama Y, Ogawa A, Okayama A. Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population. J Atheroscler Thromb 2011; 18: 89–98.
   Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian 5, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–8.
   Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 Suppl: 511–520.
   Google Scholar
• Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153:263–72.
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala 5, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989:79(1): 8–15.
   Google Scholar
• Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
   Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P. And reotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P. Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjrg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345–61.
   Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P. Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297:499–508.
   Google Scholar
• Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund 0, Agewall 5, Alegria E, Chapman M, Durrington P. Erdine 5, HalcoxJ, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias TheTask Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(1): 3–46.
   Google Scholar
• EUROASPIRE land II Group: European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357:995–1001.
   Google Scholar
• Clark AM, Hartling L, Vandermeer B, Lissel SL, McAlister FA. Secondary prevention programmes for coronary heart disease: a meta-regression showing the merits of shorter, generalist, primary care-based interventions. Eur J Cardiovasc Prey Rehabil 2007; 14: 538–46.
   Google Scholar
• Gibbs BB, Brancati FL, Chen H, Coday M, Jakicic JM, Lewis CE, Stewart KJ, Clark JM. Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study; (for the Look AHEAD Research Group). Eur J Prey Cardiol 2014; 21: 608–17.
   Google Scholar
• Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, Balasubramanyam A, Tracy RP, Kriska AP, Ballantyne CM; Look AHEAD Research Group. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. JLipidRes 2012; 53:2726–33.
   Google Scholar
• Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, Marcovina SM, Montez M, Ratner RE, Saudek CD, Sherif H, Watson KE. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. DiabetMed 2013; 30: 46–55.
   Google Scholar
• Wood DA, Kotseva K, Connolly 5, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman 0; EUROACTION Study Group. Nurse-coordi-nated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371:1999–2012.
   Google Scholar
• Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism 1980; 29: 1053–60.
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim 5, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries 5, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez 5, Op Reimer WS, Weissberg P. Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber 5, Tendera M, Widimsky P. Zamorano JL, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli 5, Hemingway H, Hakansson J, Kjeldsen SE, Larsen mL, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund 0, Zampelas A; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (1513M); European Society of Hypertension (ESH);WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prey Rehabil 2007; 14 Suppl 2: S1–113.
   Google Scholar
• Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC Guidelines for secondary prevention for patients with coronary and other aherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363–72.
   Google Scholar
• Mahajan AS, Reddy KS, Sachdeva U. Lipid profile of coronary risk subjects following yogic lifestyle intervention. Indian HeartJ 1999; 51: 37–40.
   Google Scholar
• Bijlani RL, Vempati RP, Yadav RK, Ray RB, Gupta V, Sharma R, Mehta N, Mahapatra SC. A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus. J Altem Complement Med 2005; 11: 267–74.
   Google Scholar
• Damodaran A, Malathi A, Patil N, Shah N, Suryavansihi, Marathe S.Therapeutic potential of yoga practices in modifying cardiovascular risk profiles in middle aged men and women. J Assoc Physicians India 2002; 50:633–40.
   Google Scholar
• Madanmohan, Bhavanani AB, Dayanidy G, Sanjay Z, Basavaraddi IV. Effect of yoga therapy on reaction time, biochemical parameters and wellness score of pen i and post-menopausal diabetic patients. Int J Yoga 2012; 5:10–5.
   Google Scholar
• Shantakumari N, Sequeira 5, El Deeb R. Effects of a yoga intervention on lipid profiles of diabetes patients with dyslipidemia. Indian Heart J 2013; 65: 127–31.
   Google Scholar
• Yadav RK, Magan D, Mehta N, Sharma R, Mahapatra SC. Efficacy of a short-term yoga-based lifestyle intervention in reducing stress and inflammation: preliminary results. J Altem Complement Med 2012; 18: 662–7.
   Google Scholar
• Yadav RK, Magan D, Mehta M, Mehta N, Mahapatra SC. A short-term, comprehensive, yoga-based lifestyle intervention is efficacious in reducing anxiety, improving subjective well-being and personality. Int.’ Yoga 2012; 5:134–9.
   Google Scholar
• Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu Rev Psychol 2002; 53:83–107.
   Google Scholar
• Manchanda SC, Narang R, Reddy KS, Sachdeva U, Prabhakaran D, Dharmanand 5, Rajani M, Bijlani R. Retardation of coronary atherosclerosis with yoga lifestyle intervention. J Assoc Physicians India 2000; 48:687–94.
   Google Scholar
• Fu D, Fu H, McGowan P. Shen YE, Zhu L, Yang H, Mao J, Zhu 5, Ding Y, Wei Z. Implementation and quantitative evaluation of chronic disease self-management programme in Shanghai, China: Randomized controlled trial. Bull World Health Organ 2003; 81: 174–82.
   Google Scholar
• Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131:32–47.
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97.
   Google Scholar
• Sacks FM; Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139–43.
   Google Scholar
• European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund 0, Agewall 5, Alegria E, Chapman MJ, Durrington P. Erdine 5, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur HeartJ 2011; 32:1769–818.
   Google Scholar
• Vickers KC, Remaley AT. Functional Diversity of HDL Cargo. J Lipid Res 2013 Mar 26. [Epub ahead of print]
   Google Scholar
• Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, Jung RT, Smith WC. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004; 17: 293–316.
   Google Scholar
• Rubins HB, Robins SJ, lwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993; 71:45–52.
   Google Scholar
• Frick MH, Elo 0, Haapa K, Heinonen OP, Heinsalmi P. Helo P. Huttunen JK, Kaitaniemi P. Koskinen P. Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola 5, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237–45.
   Google Scholar
• Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56: 320–8.
   Google Scholar
• Taylor RS, Brown A, Ebrahim 5, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682–92.
   Google Scholar
• Sarvottam K, Magan D, Yadav RK, Mehta N, Mahapatra SC. Adiponectin, interleukin-6, and cardiovascular disease risk factors are modified by a short-term yoga-based lifestyle intervention in overweight and obese men. JAItem Complement Med 2013; 19:397–402.
   Google Scholar